{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:03:16Z","timestamp":1762956196888,"version":"build-2065373602"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pupt.2019.101885","type":"journal-article","created":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T17:57:05Z","timestamp":1577555825000},"page":"101885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis"],"prefix":"10.1016","volume":"60","author":[{"given":"Theodoros","family":"Karampitsakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ourania","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kaponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreana","family":"Kozanidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Hillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Stavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demosthenes","family":"Bouros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Dimakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib2","article-title":"The EMBARC European Bronchiectasis Registry: protocol for an international observational study","volume":"2","author":"Barker","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.pupt.2019.101885_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2016-208481","article-title":"Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts","volume":"71","author":"McDonnell","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1378\/chest.116.2.535","article-title":"The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place?","volume":"116","author":"Siegel","year":"1999","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.pupt.2019.101885_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3947\/ic.2014.46.4.219","article-title":"Interpretation of epithelial lining fluid concentrations of antibiotics against methicillin resistant Staphylococcus aureus","volume":"46","author":"Kiem","year":"2014","journal-title":"Infect. Chemother."},{"issue":"suppl 61","key":"10.1016\/j.pupt.2019.101885_bib9","article-title":"Eradication treatment in Non CF bronchiectasis: the effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa","volume":"50","author":"Kaponi","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib10","first-page":"177","article-title":"Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. Respiration","volume":"88","author":"Rubin","year":"2014","journal-title":"Int. Rev. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib11","first-page":"740","article-title":"COUNTERPOINT: should inhaled antibiotic therapy Be used routinely for the treatment of bacterial lower respiratory tract infections in the ICU setting? No. Chest","volume":"151","author":"Kollef","year":"2017"},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/17476348.2018.1500179","article-title":"The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis","volume":"12","author":"Amaro","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"issue":"16","key":"10.1016\/j.pupt.2019.101885_bib13","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1517\/14656566.2014.959927","article-title":"Pharmacotherapy for lower respiratory tract infections","volume":"15","author":"Liapikou","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.pupt.2019.101885_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1164\/rccm.2309013","article-title":"Bronchoscopic sampling of drug concentrations: penetration to tissue is the issue","volume":"168","author":"Fish","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101885_bib15","first-page":"251792","article-title":"Greek physicians' perceptions on generic drugs in the era of austerity","volume":"2015","author":"Labiris","year":"2015","journal-title":"Sci. Tech. Rep."},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijantimicag.2010.08.013","article-title":"Antimicrobial chemotherapy and lung microdialysis: a review","volume":"36","author":"Dhanani","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"11","key":"10.1016\/j.pupt.2019.101885_bib17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/thx.49.11.1134","article-title":"Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection","volume":"49","author":"Cook","year":"1994","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib18","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","article-title":"Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia","volume":"31","author":"Boselli","year":"2003","journal-title":"Crit. Care Med."},{"issue":"10","key":"10.1016\/j.pupt.2019.101885_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.40.10.2375","article-title":"Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin","volume":"40","author":"Patel","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib21","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","article-title":"Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults","volume":"47","author":"Rodvold","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1378\/chest.125.3.965","article-title":"Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults","volume":"125","author":"Capitano","year":"2004","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib23","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jac\/dks022","article-title":"Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia","volume":"67","author":"Boselli","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ajem.2016.10.058","article-title":"Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: a retrospective cohort analysis: effectiveness of linezolid in the elderly","volume":"35","author":"Takada","year":"2017","journal-title":"Am. J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/cir907","article-title":"Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital- and ventilator-acquired pneumonia: a step forward but the battle continues","volume":"54","author":"Torres","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/dkl250","article-title":"A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia","volume":"58","author":"Alou","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/44.6.835","article-title":"Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy","volume":"44","author":"Soman","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/AAC.48.4.1215-1221.2004","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae","volume":"48","author":"Florea","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2019.101885_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-005-8203-1","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations","volume":"33","author":"Schubert","year":"2005","journal-title":"Infection"},{"key":"10.1016\/j.pupt.2019.101885_bib34","article-title":"Evaluation of epithelial lining fluid concentration of amikacin in critically ill patients with ventilator-associated pneumonia","author":"Najmeddin","year":"2018","journal-title":"J. Intensive Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1179\/joc.1995.7.4.363","article-title":"Tissue penetration and pulmonary disposition of tobramycin","volume":"7","author":"Mazzei","year":"1995","journal-title":"J. Chemother."},{"issue":"9","key":"10.1016\/j.pupt.2019.101885_bib37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00134-007-0688-x","article-title":"Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients","volume":"33","author":"Boselli","year":"2007","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.pupt.2019.101885_bib39","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1128\/AAC.03742-14","article-title":"In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus","volume":"58","author":"MacVane","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/03007990903512057","article-title":"The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid","volume":"26","author":"Stein","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib41","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1183\/09031936.96.09081601","article-title":"Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa","volume":"9","author":"Evans","year":"1996","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib42","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","article-title":"Effect of sputum bacteriology on the quality of life of patients with bronchiectasis","volume":"10","author":"Wilson","year":"1997","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pupt.2019.101885_bib44","first-page":"1","article-title":"Cost of hospitalizations due to exacerbation in patients with non-cystic fibrosis bronchiectasis","author":"de la Rosa Carrillo","year":"2018","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02497-2017","article-title":"Pseudomonas aeruginosa infection and exacerbations in bronchiectasis: more questions than answers","volume":"51","author":"Martinez-Garcia","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.arbres.2018.07.002","article-title":"Prognostic value of frequent exacerbations in bronchiectasis: the relationship with disease severity","volume":"55","author":"Martinez-Garcia","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.pupt.2019.101885_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/COPD.S121943","article-title":"Predicting high risk of exacerbations in bronchiectasis: the E-FACED score","volume":"12","author":"Martinez-Garcia","year":"2017","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib49","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Marshall","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/157488712799363280","article-title":"Use of antibiotics in bronchiectasis","volume":"7","author":"King","year":"2012","journal-title":"Rev. Recent Clin. Trials"},{"issue":"22","key":"10.1016\/j.pupt.2019.101885_bib51","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/00003495-200363220-00015","article-title":"Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 56","key":"10.1016\/j.pupt.2019.101885_bib52","article-title":"Pharmacokinetics of tobramycin nebulizer solution (300mg\/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and <em>Pseudomonas aeruginosa<\/em> infection","volume":"40","author":"Govoni","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jac\/dkv399","article-title":"Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients","volume":"71","author":"van Koningsbruggen-Rietschel","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.pupt.2019.101885_bib54","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1016\/j.xphs.2017.06.010","article-title":"Population pharmacokinetics of tobramycin inhalation solution in pediatric patients with cystic fibrosis","volume":"106","author":"Wang","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib56","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"BARKER","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib58","doi-asserted-by":"crossref","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with <em>Pseudomonas aeruginosa<\/em>","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib59","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"Scheinberg","year":"2005","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.pupt.2019.101885_bib60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000438490","article-title":"Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"90","author":"Orriols","year":"2015","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149768","article-title":"Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients","volume":"11","author":"Hoppentocht","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib65","first-page":"9","article-title":"Nebulized gentamicin as an alternative to nebulized tobramycin for tracheitis in pediatric patients","volume":"22","author":"Chen","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101885_bib67","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02081963."},{"key":"10.1016\/j.pupt.2019.101885_bib68","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00775138."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rmed.2011.11.018","article-title":"Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis","volume":"106","author":"White","year":"2012","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib70","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.pupt.2019.101885_bib71","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.201404-0638ED","article-title":"Nebulized colistin for non\u2013cystic fibrosis bronchiectasis: d\u00e9j\u00e0 vu all over again?","volume":"189","author":"Metersky","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"suppl 60","key":"10.1016\/j.pupt.2019.101885_bib72","article-title":"Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection","volume":"48","author":"Matto","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2019.101885_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.regg.2014.09.005","article-title":"[Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection]","volume":"50","author":"Tabernero Huguet","year":"2015","journal-title":"Rev. Esp. Geriatr. Gerontol."},{"issue":"9","key":"10.1016\/j.pupt.2019.101885_bib74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib75","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"Respire 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib78","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"Respire 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib79","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02444-2017","article-title":"RESPIRE: breathing new life into bronchiectasis","volume":"51","author":"Chotirmall","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.pupt.2019.101885_bib80","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/jac\/dkx541","article-title":"Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers","volume":"73","author":"Felton","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.pupt.2019.101885_bib81","first-page":"53","article-title":"New insight into the clinical pharmacokinetics of cefaclor: tissue penetration","volume":"12","author":"Mazzei","year":"2000","journal-title":"J. Chemother."},{"issue":"10","key":"10.1016\/j.pupt.2019.101885_bib82","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib83","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/AAC.00144-09","article-title":"Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole","volume":"53","author":"Rodvold","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.pupt.2019.101885_bib84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/46.2.319","article-title":"Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid","volume":"46","author":"Allegranzi","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.pupt.2019.101885_bib85","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2005.08.015","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem","volume":"26","author":"Conte","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.pupt.2019.101885_bib86","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.pupt.2019.101885_bib87","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0954-6111(05)80262-8","article-title":"Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration","volume":"87","author":"Baldwin","year":"1993","journal-title":"Respir. Med."},{"issue":"9","key":"10.1016\/j.pupt.2019.101885_bib88","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/thx.43.9.715","article-title":"Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa","volume":"43","author":"Honeybourne","year":"1988","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.pupt.2019.101885_bib89","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919303220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919303220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:29:22Z","timestamp":1761082162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919303220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":89,"alternative-id":["S1094553919303220"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101885","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101885"}}